We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

02 Jun 2026 - 04 Jun 2026
17 Jun 2026 - 19 Jun 2026
05 Oct 2026 - 06 Oct 2026

Aspirin Reduces Risk of First Heart Attack by 32%

By HospiMedica staff writers
Posted on 05 Dec 2002
A detailed meta-analysis of five randomized trials has shown that aspirin conclusively reduces the risk of a first heart attack by 32% and reduces the combined risk of heart attack, stroke, and vascular death by 15%. More...
The findings were presented at the 2002 Scientific Sessions of the American Heart Association (AHA) in Chicago, IL (USA).

"These data, along with the findings that aspirin reduces the risk of death by 23% if given during a heart attack, demonstrate that more widespread and appropriate use of aspirin in secondary and primary prevention would avoid many premature deaths and heart attacks,” said Charles H. Hennekens, M.D., co-director of cardiovascular research at Mount Sinai Medical Center & Miami Heart Institute (Miami, FL, USA), who led the first randomized trial of aspirin in primary prevention. The AHA recommends aspirin for all men and women whose 10-year risk of a first coronary event is 10% or greater.

Another study presented by researchers at the University of North Carolina (Chapel Hill, USA) at the AHA meeting found that continuing aspirin together with an anticlotting drug such as clopidogrel for one year reduced heart attacks, repeated angioplasties, strokes, and heart fatalities by 26.9%, versus taking the anticlotting drug alone for only four weeks.

A study by Argentine researchers presented at the AHA meeting showed that a program of regular follow-up calls by trained nurses to patients with chronic heart failure could reduce hospital admissions for heart failure by 28%.




Related Links:
Miami Heart Institute

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Hypodermic Syringe
SurTract™ Safety Syringe
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The Elyra TFL System uses thulium fiber laser technology for efficient stone dusting and reduced stone migration, with an air-cooled design for quieter, more compact operation (photo courtesy of BD

BD Launches Elyra Laser Platform for Kidney Stone and Soft Tissue Procedures

BD (Becton, Dickinson and Company) has introduced the Elyra Thulium Fiber Laser (TFL) System, an advanced laser platform developed to complete its kidney stone care portfolio for urology teams.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.